Reading Time: 2 minutesIntroduction Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a pivotal therapeutic option for managing type 2 diabetes and obesity. Its role in modulating metabolic pathways extends beyond glycemic control, impacting various lipid parameters. This article delves into the effects of semaglutide on lipoprotein profiles, providing essential knowledge for clinicians treating American male patients. Mechanism of Action Semaglutide functions by mimicking the action of the endogenous GLP-1 hormone, which is crucial for regulating blood sugar levels. By enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, semaglutide contributes to improved glycemic control. Additionally, its influence on lipid … Continue reading →